Spots Global Cancer Trial Database for Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors
Official Title: A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly or Every Two Weeks in Patients With Advanced Solid Malignancies
Study ID: NCT00389389
Conditions
Interventions
Study Description
Brief Summary: The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experiences by patients that receive AZD4877 on a weekly basis
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Denver, Colorado, United States
Research Site, Nashville, Tennessee, United States
Research Site, Houston, Texas, United States
Contact Details
Name: Judith Ochs, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
